I attempted to run RDKit locally to compute these descriptors fresh, but the sandbox declined the permission prompt for script execution (non-interactive session, no one to approve it). So the numbers below are the standard literature/database values for aspirin (PubChem CID 2244, DrugBank DB00945, ChEMBL25) rather than a live recomputation — I'll flag anywhere a different calculator (RDKit Crippen vs. XLogP3) would give a slightly different number.

**Assumption:** you gave aspirin's SMILES as the example (`CC(=O)Oc1ccccc1C(=O)O`), so that's the worked compound below. Swap in your actual hit's SMILES and the same pipeline applies.

## 1. Physicochemical descriptors
| Descriptor | Value | Source/method |
|---|---|---|
| Formula / MW | C9H8O4 / 180.16 g/mol | PubChem CID 2244 |
| cLogP | ~1.2 (XLogP3) / ~1.31 (RDKit Crippen) | PubChem computed property; RDKit `Crippen.MolLogP` |
| TPSA | 63.6 Å² | Ertl 2000 method (PubChem & RDKit agree) |
| HBD / HBA | 1 / 4 | PubChem H-bond donor/acceptor count (Lipinski N+O convention) |
| Rotatable bonds | 3 | PubChem rotatable bond count |
| Aromatic rings | 1 | structure |
| Molar refractivity | ~44.9 | Crippen MR |
| Heavy atoms | 13 | structure |

## 2. Rule-set flags
| Rule | Criteria vs. aspirin | Verdict |
|---|---|---|
| **Lipinski Ro5** | MW≤500 (180.16✓), cLogP≤5 (1.2✓), HBD≤5 (1✓), HBA≤10 (4✓) | **0 violations — pass** |
| **Veber** | RotB≤10 (3✓), TPSA≤140 Å² (63.6✓) | **Pass** — predicts good oral bioavailability |
| **Egan (BOILED-Egg)** | TPSA≤131.6, WLogP roughly −1 to 5.9 | **Pass**, sits in the "high GI absorption" region |
| **Muegge** | MW **200–600** (180.16 — **below floor**), logP −2..5✓, TPSA≤150✓, rings≤7✓, C>4✓, heteroatoms>1✓, RotB≤15✓, HBA≤10✓, HBD≤5✓ | **1 violation (MW<200)** — a known artifact of Muegge's stricter lower MW bound; several small approved acids (salicylic acid, ibuprofen-adjacent fragments) fail this same way, so treat it as a minor formal miss, not a red flag |

## 3. Structural alerts
- **PAINS** (Baell & Holloway 2010 substructure set): no hits — no rhodanine, catechol, quinone, or other reactive/promiscuous motifs present.
- **BRENK** (Brenk et al. 2008, 105-pattern unwanted-functionality filter): no standard hits in typical implementations (FAF-Drugs4/DataWarrior filters).
- **Caveat outside the formal catalogs:** the phenolic **acetate ester** is chemically/metabolically labile (spontaneous + esterase-mediated hydrolysis to salicylic acid) — not flagged by PAINS/Brenk substructure matching, but worth noting manually as a stability liability for any hit sharing this motif.

## 4. Reported assay-level ADMET data (same compound / close analogs)
| Endpoint | Finding | Source |
|---|---|---|
| CYP inhibition | Not a potent perpetrator of major CYPs at therapeutic concentration; salicylate shows weak CYP2C9 inhibition only at high (supratherapeutic) concentrations | DrugBank DB00945, literature DDI reviews |
| hERG | No meaningful hERG block reported; IC50 far above therapeutic plasma levels — low cardiotoxicity risk signal | Published hERG panel screens of NSAIDs |
| Metabolic/microsomal stability | Parent aspirin is hydrolyzed rapidly by plasma/tissue **esterases** (not CYP-driven), t½ ~15–20 min, to salicylic acid; salicylate is then cleared via glycine/glucuronide conjugation, with CYP2C9-mediated hydroxylation to gentisic acid as a minor route | DrugBank DB00945 metabolism section |
| Plasma protein binding | Aspirin itself ~50% bound; active metabolite salicylate is highly and **saturably** albumin-bound (~80–90% at low dose, falling at high dose) → nonlinear PK | DrugBank DB00945; classic salicylate PK literature |
| Permeability | High passive transcellular permeability as an un-ionized weak acid (pKa~3.5) at gastric pH; rapid absorption in stomach/proximal intestine | BCS/absorption literature on aspirin |
| Solubility | ~3–4 mg/mL aqueous solubility at 25 °C, pH-dependent (rises above pKa) | PubChem experimental solubility data |

## 5. Synthesized picture
Aspirin reads as a clean, low-risk early hit on every computable axis: full Lipinski/Veber/Egan compliance, no PAINS/Brenk substructure hits, and no hERG or major CYP liability in reported assays. The only rule-set flag (Muegge MW floor) is a known false-positive for small acidic drugs, not a real developability concern. The one genuine caveat that doesn't show up in any descriptor or alert catalog is the ester's intrinsic hydrolytic lability — it drives aspirin's short parent-compound half-life and would be the first thing to check by analogy if your actual screening hit carries a similar acyl-labile group. The nonlinear (saturable) protein binding of the active moiety is the other flag worth carrying into any PK modeling, since it will make simple linear PPB-correction assumptions inaccurate at higher doses.